Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 17, 2020 09:00 ET | Source: Tufts Center for the Study of Drug Development

Drug Developers Are Responding to Evolving Data Demands with New Strategies and Tactics, According to Tufts Center for the Study of Drug Development

BOSTON, March 17, 2020 (GLOBE NEWSWIRE) -- Rapid growth in data volume and the diversity of data sources are leading drug developers to plan and adopt data management strategies and tactics to help...
January 28, 2020 09:00 ET | Source: Tufts Center for the Study of Drug Development

Drug Developers Are Making Strides in Streamlining Patient Recruitment and Retention for Clinical Trials, According to Tufts Center for the Study of Drug Development

BOSTON, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Efforts by drug developers during the last decade to improve recruitment and retention of patients for clinical trials appear to be paying off, as...
November 14, 2019 09:00 ET | Source: Tufts Center for the Study of Drug Development

New Study from Tufts Center for the Study of Drug Development Establishes Benchmarks for Vendor Qualification Process

BOSTON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- While more than 90% of all contract vendor assessments conducted by drug sponsors ultimately lead to vendors being qualified to provide services, large...
September 03, 2019 09:00 ET | Source: Tufts Center for the Study of Drug Development

Cancer Drugs Now Account for 27% of all New Drug Approvals in the U.S., According to Tufts Center for the Study of Drug Development

BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Cancer drugs currently account for 27% of all new drug approvals in the United States since 2010, a dramatic increase from the 4% share of the 1980s, a...
July 09, 2019 09:00 ET | Source: Tufts Center for the Study of Drug Development

Growth in Rare Disease R&D Is Challenging Development Strategy and Execution, According to Tufts Center for the Study of Drug Development

BOSTON, July 09, 2019 (GLOBE NEWSWIRE) -- Rare disease drug development, which now accounts for nearly one-third of all drugs in active R&D worldwide, presents scientific and operational...
May 07, 2019 09:00 ET | Source: Tufts Center for the Study of Drug Development

Adoption of Artificial Intelligence Is High Across Pharmaceutical Industry, According to Tufts Center for the Study of Drug Development

BOSTON, May 07, 2019 (GLOBE NEWSWIRE) -- The pharmaceutical industry is adopting artificial intelligence (AI) on numerous fronts, from discovery and clinical development to risk assessment and...
March 05, 2019 09:00 ET | Source: Tufts Center for the Study of Drug Development

Drug Development Outsourcing Outpaces Internal Spending but Remains Tactical and Reactive, According to Tufts Center for the Study of Drug Development

BOSTON, March 05, 2019 (GLOBE NEWSWIRE) -- Drug sponsors spend more on contract research organizations (CROs) to help develop new medicines than they do on internal staff and infrastructure, but...
January 08, 2019 09:00 ET | Source: Tufts Center for the Study of Drug Development

U.S. Continues to Lead New Drug R&D, but Asia-Pacific is Starting to Rise, According to the Tufts Center for the Study of Drug Development

BOSTON, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Recent launches of new active substances (NAS) and a strong R&D pipeline indicate that recent global drug development not only has been robust, but also...
November 13, 2018 09:00 ET | Source: Tufts Center for the Study of Drug Development

Global Biotech Product Development Expected to Continue Its Multi-Decade Surge, According to the Tufts Center for the Study of Drug Development

BOSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- With more than 500 Phase III clinical trials now underway for biotech products worldwide, the multi-decade surge in new biopharmaceutical approvals is...
September 11, 2018 09:00 ET | Source: Tufts Center for the Study of Drug Development

CNS Drugs Take 20% Longer to Develop and 38% Longer to Approve vs. Non-CNS Drugs, According to the Tufts Center for the Study of Drug Development

BOSTON, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Developing drugs to treat central nervous system (CNS) disorders on average required 20% more time than other drugs that won marketing approval in the...